CRCs can be classified based on the presence of mutations in oncogenes such as KRAS, BRAF, and PIK3CA. Among the affected oncogenes, KRAS mutations are present in 35–40% of CRC cases, and the presence of a KRAS mutation is an early phenomenon in CRC [3–5]. This evidence concerns the gene PIK3CA and colorectal carcinoma.